CollPlant 6-K: rhCollagen distribution expansion in U.S. and Canada

CollPlant Biotechnologies filed a Form 6-K reporting it issued a press release titled “CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada.” The release is furnished as an exhibit to the report.

Rhea-AI Filing Summary

CollPlant Biotechnologies filed a Form 6-K reporting it issued a press release titled “CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada.” The release is furnished as an exhibit to the report. The update highlights broader distribution coverage for the company’s rhCollagen across the U.S. and Canada.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CLGN announce in this Form 6-K?

CollPlant reported it issued a press release titled “CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada.”

When was the press release issued by CLGN?

The press release was issued on October 27, 2025.

What regions are covered by the distribution expansion noted by CLGN?

The expansion concerns the United States and Canada.

What is the filing type submitted by CLGN?

It is a Form 6-K filed as a report of a foreign private issuer.

Does the 6-K include exhibits related to the announcement?

Yes. The press release is attached as an exhibit and incorporated by reference.

Who signed the CLGN 6-K?

It was signed by Eran Rotem, Deputy CEO and Chief Financial Officer, dated October 27, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/27/2025 - 07:16 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

On October 27, 2025, CollPlant Biotechnologies Ltd. issued a press release entitled “CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada”.

Attached hereto and incorporated by reference herein are the following exhibits:

99.1 Press Release, dated October 27, 2025

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.
Date: October 27, 2025	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer

2